ADC Therapeutics Announces ZYNLONTA® Updates in Japan
ADC Therapeutics' Japanese licensing partner Tanabe Pharma filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare for ZYNLONTA in relapsed or refractory DLBCL after two or more lines of systemic therapy. The filing is based on a Phase 1/2 Japanese bridging study showing a 58.1% overall response rate and 41.9% complete response rate, consistent with the pivotal global LOTIS-2 study with no new safety concerns. Tanabe Pharma also sublicensed Japanese commercialization rights to Nippon Shinyaku, an established oncology commercial player.
Key figures
- Drug Name
- ZYNLONTA (loncastuximab tesirine-lpyl)
- Phase Of Trial
- Phase 1/2
- Overall response rate
- 58.1%
- Complete response rate
- 41.9%
- Median followup months
- 15.21
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.